Genmab — Marts 2017
-
Mange tak
-
-
Janssen's sidste bemærkning til NICE appraisal af Dara kombier:The combination of daratumumab with lenalidomide and dexamethasone is unlikely to be cost-effective, even at zero price as a result of the borderline cost-effectiveness of lenalidomide and dexamethasone. Janssen would like to highlight that as we are not the manufacturer of lenalidomide, we have no influence on the pricing of lenalidomide and would like to discuss this further with NICE as a matter of urgency. This situation only ser
-
God morgen.
-
-
I morgen er der Darzalex US-salgstal. Sidste måned var tallet USD 61 mio. Januar havde 20 arbejdsdage mod 19 i februar. Så kan salget blive på 61 mio. USD eller derover, så indikerer det en stigning på mindst 5% på dagsbasis.
-
Der er faktisk 20 dage i februar
og i USA var der også 20 arbejdsdage i januar. Januar viste så en ekstra stor stigning, og det bliver spændende at se om det var en normalmåned eller om den var præget af at det havde været jul. Mit gæt er at den lander på 65 mio $ i feb. selv om 64 ville være over Genmab's eget estimat.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind